Australian prescription medicine decision summaries
Search our decision summaries for the registration of new prescription medicines.
For more information, visit the About Australian prescription medicine decision summaries information page.
We have redesigned our prescription medicine decision summaries (AusPMDSs) to make it easier to understand how prescription medicines are registered in Australia.
The redesigned AusPMDSs will offer clear, accessible information about recent medicine registration decisions.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Search
262 result(s) found, displaying 176 to 200
-
-
-
-
-
-
-
-
-
-
-
Prescription medicine decision summaryAustralian prescription medicine decision summary
-
-
-
-
-
Prescription medicine decision summaryAustralian prescription medicine decision summary
-
-
-
-
-
Prescription medicine decision summaryAustralian prescription medicine decision summary
-
-
Prescription medicine decision summaryTGA decision: Ovaleap (follitropin alfa) is approved to treat anovulatory infertility in woman who are unresponsive to clomiphene citrate.
-
Prescription medicine decision summaryTGA decision: Spravato (esketamine hydrochloride) is approved for the treatment of treatment resistant depression.
-
Prescription medicine decision summaryTGA decision: Ruxience (rituximab) is approved to treat non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, GPA and MPA.